Ranbaxy approved to manufacture, market cardiovascular drug in Canada

GURGAON, India Canada’s drug regulation authority has given an Indian drug maker approval to manufacture a generic cardiovascular drug in the country.

Ranbaxy Labs announced Tuesday that Health Canada had granted it approval to manufacture and market Ran-Simvastatin (simvastatin) tablets in the 5 mg, 10 mg, 20 mg, 40 mg and 80 mg strengths.

Generic versions of simvastatin have sales of $153 million, according to IMS Health data.